TPIRC - Tau Pathology and Immunotherapy Research Center

Tau Pathology

Overview

Tau Pathology

Overview

Tau pathology represents one of the hallmark features of Alzheimer's disease (AD) and several other neurodegenerative disorders collectively known as tauopathies. The accumulation of abnormal tau protein into neurofibrillary tangles (NFTs) correlates more closely with cognitive impairment than amyloid plaque burden, making tau a critical therapeutic target. Understanding tau biology is essential for developing disease-modifying therapies for AD and related disorders. [@ghashghaie2023]

Tau Protein and the microtubule-associated protein tau (MAPT) Gene

The MAPT gene is located on chromosome 17q21.31 and encodes the tau protein, a microtubule-associated protein that plays essential roles in neuronal physiology [1]. The gene spans approximately 150 kb and has been extensively studied due to its central role in neurodegeneration. The discovery of MAPT mutations causing frontotemporal dementia established tauopathy as a genetic disease and confirmed the pathogenic importance of tau pathology. [@karantaka2022]

Gene Structure

The MAPT gene contains 16 exons with complex alternative splicing patterns. Six isoforms are expressed in the adult human brain, ranging from 352 to 441 amino acids in length [2]. The isoforms differ in the presence of: [@wu2016]

• N-terminal inserts: Exons 2 and 3 can be included or excluded, generating 0, 1, or 2 inserts (0N, 1N, 2N tau)
• Microtubule-binding repeats: Exon 10 inclusion gives 4-repeat (4R) tau, exclusion gives 3-repeat (3R) tau

• 4R tau binds microtubules more strongly due to additional repeat
• 4R tau is more prone to aggregation
• The 3R:4R ratio is tightly regulated (1:1) in the normal brain
• Splicing of exon 10 is critical - mutations causing FTDP-17 disrupt this regulation

Protein Structure

Tau protein consists of several functional domains [3]: [@blennow2019]

• N-terminal projection domain (1-150 aa): Projects away from microtubules and interacts with neuronal plasma membrane, modulating microtubule spacing and serving as a scaffold for signaling complexes
• Proline-rich region (150-250 aa): Contains multiple phosphorylation sites for regulatory control and mediates protein-protein interactions with Src family kinases
• Microtubule-binding domain (250-400 aa): Contains 3 or 4 tandem repeats of 31-32 amino acids each, critical for microtubule binding through ionic interactions
• C-terminal region (400-441 aa): Provides structural stability and contains the sequences needed for filament assembly

Tau Physiology

Microtubule Stabilization

In its normal state, tau protein plays essential roles in the brain [5]: [@sigurdsson2016]

• Microtubule assembly: Tau promotes microtubule polymerization by lowering the critical concentration required for assembly through its repeat domains
• Microtubule stability: Tau protects microtubules from depolymerization by cold, calcium, and nocodazole treatment
• Axonal transport: Tau enables efficient axonal transport by providing stable tracks for kinesin and dynein motor proteins
• Neuronal polarity: Tau helps maintain axonal identity by specifying axonal microtubules versus dendritic microtubules
• Synaptic function: Tau is present at synapses and modulates neurotransmission, long-term potentiation, and memory formation

Phosphorylation Regulation

Tau function is tightly regulated by phosphorylation in healthy neurons [6]: [@congdon2018]

• Normal tau has 2-3 moles of phosphate per mole of protein
• Phosphorylation reduces tau's microtubule-binding affinity, modulating its association with microtubules
• Multiple kinases phosphorylate tau at specific sites:
• GSK-3β (Glycogen Synthase Kinase-3 beta): Major tau kinase, hyperphosphorylates tau at >20 sites including Ser202, Thr205, Ser396
• CDK5 (Cyclin-dependent kinase 5): Important in brain development and disease, activated by p35/p39
• MAPK (ERK1/2): Stress-activated kinases that respond to excitotoxicity
• JNK (c-Jun N-terminal kinase): Apoptosis-related signaling
• PKA (Protein kinase A): cAMP-dependent phosphorylation
• Phosphatases dephosphorylate tau:
• PP2A (Protein phosphatase 2A): Accounts for >70% of tau phosphatase activity and is inhibited in AD
• PP1 (Protein phosphatase 1)
• PP2B (Calcineurin): Calcium-dependent, less important for tau

Normal Tau Post-Translational Modifications

Beyond phosphorylation, tau undergoes multiple post-translational modifications [7]: [@klein2009]

• Glycosylation: O-GlcNAcylation affects phosphorylation status and may be protective; levels decrease with age
• Acetylation: Can regulate tau function at Lys residues; increased acetylation seen in AD
• Ubiquitination: Tags tau for degradation via proteasome
• Sumoylation: May protect tau from degradation
• Methylation: Emerging modification with unclear function
• Truncation: Proteolytic cleavage generates various fragments, some toxic

Tau in Alzheimer's Disease

Hyperphosphorylation

In AD, tau becomes abnormally hyperphosphorylated, which is a critical pathological event [8]: [@hernandez2020]

• Phosphorylation increases to 5-9 moles phosphate per mole tau (2-3x normal)
• Pathological phosphorylation at 40+ sites has been identified across the protein
• Key AD-specific phosphorylation sites include:
• Ser202/Thr205 (AT8 epitope) - early marker, detected in pretangle neurons
• Ser396 (PHF-1 epitope) - correlates strongly with NFT burden
• Thr212/Ser214 - specific to AD pathology
• Ser422 - found in AD but not in other tauopathies

• GSK-3β activation through multiple pathways including Akt, Wnt, and PI3K dysregulation
• CDK5 dysregulation via p25 accumulation (cleavage product of p35)
• PP2A activity reduction in AD brain (~50% decrease)
• Kinase-phosphatase imbalance favoring pathological phosphorylation

Pathological Aggregation

Hyperphosphorylated tau dissociates from microtubules and aggregates into toxic species [9]: [@jack2018]

The aggregation process is driven by:

• Hyperphosphorylation reducing solubility and increasing net negative charge
• Conformational changes exposing aggregation-prone regions (PHF6 motif)
• Post-translational modifications promoting aggregation (acetylation, truncation)
• Seed-dependent polymerization (prion-like mechanism)

Neurofibrillary Tangles

NFTs are intracellular inclusions composed of PHFs and SFs [10]:

• Found in AD brain in a characteristic pattern reflecting disease progression
• Progress from entorhinal cortex (stage I/II) to hippocampus (III/IV) to neocortex (V/VI)
• Correlate strongly with neuronal loss and brain atrophy
• Braak staging (I-VI) is based on NFT distribution:
• Stages I-II: Transentorhinal region (preclinical)
• Stages III-IV: Limbic region (incipient AD)
• Stages V-VI: Isocortical region (fully developed AD)

Tau Spreading

Recent evidence supports prion-like propagation of tau pathology [11]:

• Pathological tau can be taken up by neurons through endocytosis
• Trans-synaptic spread along neural circuits provides explanation for staged progression
• Interneuronal transfer of pathological tau seeds initiates aggregation
• Exosomal secretion and uptake between cells contributes to spread
• Inoculation of tau seeds can cause pathology in animal models, confirming prion-like behavior

Tauopathies

Tau pathology is present in multiple neurodegenerative diseases, classified as primary or secondary tauopathies [12]:

Alzheimer's Disease

• Most common tauopathy, affecting ~50 million people worldwide
• Contains both 3R and 4R tau in NFTs
• Mixed pathology: amyloid plaques + NFTs + other lesions
• NFTs closely correlate with cognitive impairment (r=0.79 with cognitive scores)

Primary Tauopathies

Progressive Supranuclear Palsy (PSP)

• 4R tau predominant in globose NFTs
• Subcortical structures severely affected (basal ganglia, brainstem)
• Clinical features: vertical gaze palsy, axial rigidity, parkinsonism, falls
• Richardson's syndrome most common phenotype
• H1 haplotype is major genetic risk factor

Corticobasal Degeneration (CBD)

• 4R tau predominant
• Asymmetric cortical and subcortical involvement
• Clinical features: apraxia, rigidity, myoclonus, alien limb phenomenon
• Often misdiagnosed as Parkinson's disease

Frontotemporal Dementia with Parkinsonism-17 (FTDP-17)

• Caused by MAPT mutations (50+ identified)
• Variable 3R:4R ratios depending on mutation type
• Frontotemporal lobar degeneration with behavioral changes
• Parkinsonsim and cognitive decline

Pick's Disease

• 3R tau predominant in Pick bodies
• Round, spherical tau inclusions without PHF structure
• Frontotemporal lobar degeneration with personality changes
• Spongiform changes in affected regions

Chronic Traumatic Encephalopathy (CTE)

• Contains both 3R and 4R tau
• Associated with repetitive head trauma (sports, military)
• Mood, cognitive, and motor symptoms
• Progressive dementia, often decades after trauma

Secondary Tauopathies

• Parkinson's disease with dementia: Variable tau co-pathology in limbic regions
• Dementia with Lewy bodies: Some tau co-pathology common
• Amyotrophic lateral sclerosis: Occasional tau pathology in motor neurons
• Down syndrome: Age-related tau accumulation with amyloid pathology

Mechanisms of Tau Toxicity

Loss of Function

The loss of normal tau function contributes to neurodegeneration [13]:

• Reduced microtubule stabilization leading to axonal transport defects
• Impaired axonal transport causing synaptic dysfunction and loss
• Loss of neuronal polarity and dendritic abnormalities
• Disrupted microtubule organization and dynamics

Gain of Toxic Function

Pathological tau gains toxic properties through multiple mechanisms [14]:

• Oligomeric tau is the most toxic species, directly disrupts synapses
• Direct binding to mitochondria causing dysfunction and energy failure
• Induction of oxidative stress through multiple pathways
• Activation of neuroinflammation through glial activation
• Seeding and spreading of pathology to other neurons
• ER stress and unfolded protein response activation
• DNA damage and genomic instability
• Calcium dysregulation and excitotoxicity

Specific Vulnerabilities

Tau pathology affects multiple cellular systems:

• Mitochondrial dysfunction: Tau-VDAC interaction disrupts mitochondrial membrane potential
• ER stress: Accumulation triggers all three branches of UPR
• Synaptic loss: Precedes NFT formation by months to years
• Axonal degeneration: Begins before cell body involvement
• Nuclear dysfunction: Tau in nucleus may affect gene expression

Tau and Neurodegeneration

Relationship to Amyloid

The amyloid-tau relationship is complex and bidirectional [15]:

• Amyloid may accelerate tau pathology through unknown mechanisms (toxic gain of function)
• Tau pathology correlates more strongly with cognitive impairment than amyloid
• Both pathologies may be necessary for full AD manifestation
• Therapeutic targeting of both may be necessary for optimal benefit

Neuronal Loss

NFTs closely correlate with neuronal loss and cognitive decline:

• Neurons containing NFTs eventually die via apoptosis or necrosis
• Synapse loss precedes NFT formation and predicts cognitive decline
• Atrophy correlates with NFT burden better than amyloid plaques
• Regional vulnerability reflects both connectivity patterns and intrinsic susceptibility

Diagnostic Biomarkers

CSF Biomarkers

Cerebrospinal fluid biomarkers for tau pathology [16]:

• Total tau (t-tau): Elevated in AD (~2-3x controls), reflects neuronal damage
• Phosphorylated tau (p-tau):
• p-tau181: Most validated, AD-specific, elevated 3-4x in AD
• p-tau217: High diagnostic accuracy, can differentiate AD from other dementias
• p-tau235: Less studied but also elevated in AD
• Decreased Aβ42/Aβ40 ratio with elevated tau confirms AD diagnosis

Imaging Biomarkers

Tau PET imaging has revolutionized research and clinical trials [17]:

• Flortaucipir (AV-1451): High-affinity tracer for PHF/SF tau
• Regional tau PET signal correlates with atrophy and cognitive deficits
• Tau PET predicts cognitive decline better than amyloid PET
• Newer tracers: PI-2620, MK-6240, JNJ-311 show improved properties
• Tau burden detected before symptomatic stage in familial AD

Fluid Biomarkers

Emerging blood-based biomarkers offer less invasive options:

• Plasma p-tau181: Elevated in AD, useful for screening
• Plasma p-tau217: High accuracy for AD diagnosis
• Plasma p-tau231: Early marker in preclinical AD
• Extracellular tau in interstitial fluid via microdialysis
• Tau in extracellular vesicles reflects brain pathology

Therapeutic Strategies

Anti-Tau Therapies in Development

Immunotherapy

Active and passive vaccination approaches have advanced to clinical trials [18]:

• Active vaccination: AADvac1 (completed phase 2, antibody response), ACI-35 (phase 1/2)
• Passive antibodies:
• Semorinemab (failed in AD)
• Gosuranemab (failed in AD)
• Bepranemab (ongoing)
• Lintelizumab (phase 2)
• Target extracellular and intracellular tau
• Challenges: intracellular delivery, safety, efficacy

Kinase Inhibitors

Target tau kinases to reduce pathological phosphorylation [19]:

• GSK-3β inhibitors: Lithium (mixed results), tideglusib (failed)
• CDK5 inhibitors: In development, challenges with toxicity
• Challenges: pleiotropic kinase functions, blood-brain barrier

Phosphatase Activators

• PP2A activation strategies being explored
• Paradox: lithium inhibits GSK-3β but also PP2A

Aggregation Inhibitors

Small molecules targeting tau-tau interaction are promising [20]:

• Methylene blue derivatives (leuco-methylthioninium)
• Rationally designed compounds based on tau structure
• Natural products and repurposed drugs
• Challenges: potency, brain penetration, toxicity

Microtubule Stabilizers

• Taxanes (paclitaxel, docetaxel): brain penetration issue
• Epothilone D (failed in clinical trials)
• Davunetide (failed in PSP)

Tau Degradation

• Autophagy enhancers (rapamycin, trehalose)
• Proteasome activators
• Molecular degron approaches (PROTAC, molecular glues)
• Anti-tau antibodies may enhance clearance

Symptomatic Approaches

• Acetylcholinesterase inhibitors: modest benefit, cholinergic modulation
• NMDA receptor antagonists: symptomatic relief in moderate AD
• Cognitive enhancers: ongoing development
• Non-pharmacological: cognitive training, exercise

Research Models

Cell Models

• Tau-transfected cell lines (HEK293, SH-SY5Y) for aggregation studies
• iPSC-derived neurons from tauopathy patients for personalized studies
• Tau knockout cells: viable but with cytoskeletal defects

Animal Models

Transgenic mouse models expressing mutant human tau [21]:

• P301S: Fast aggregation, early pathology, neuroinflammation
• P301L: Progressive NFTs, memory deficits
• rTg4510: Inducible expression, allows temporal control
• APP/PS/tau: Triple transgenic combining amyloid and tau
• AAV-mediated expression for rapid model generation
• Tau knockout mice show minimal phenotype

In Vitro Systems

• Purified protein aggregation assays with seeded polymerization
• Cell-free systems recapitulating PHF formation
• Brain organoid models for developmental studies
• 3D neuronal cultures for drug screening

Genetics of Tauopathies

MAPT Mutations

Over 100 pathogenic MAPT mutations cause FTDP-17 [22]:

• Missense mutations: affect protein function, reduce microtubule binding
• Splicing mutations: exon 10 mutations alter 3R:4R ratio
• 4R-inducing mutations: most common, cause frontotemporal dementia
• Many mutations increase tau aggregation propensity

Risk Factors

• H1 haplotype: Major genetic risk factor for PSP and CBD
• MAPT H2 haplotype may be protective
• Multiple GWAS loci identified near MAPT
• Gene-environment interactions (trauma, toxins)

Tau and Aging

Age-related changes in tau biology [23]:

• Subtle phosphorylation increases with normal aging
• Preclinical tau pathology in ~20-30% of cognitively normal elderly
• Some elderly have NFTs without dementia (cognitive reserve)
• Reserve and resilience factors modify pathology impact on function

Biomarker Development

Prognostic Applications

• CSF p-tau predicts progression from MCI to AD
• Baseline tau PET predicts rate of cognitive decline
• Longitudinal tau change correlates with clinical outcomes

Treatment Response

• Tau PET change as treatment response marker
• CSF biomarker modulation with therapy
• Fluid biomarker pharmacodynamics

Emerging Concepts

Tau Oligomers as Therapeutic Target

• Not just fibrils, but oligomers are most toxic
• Multiple therapeutic approaches target oligomers
• Biomarker potential for oligomer-specific assays

Tau Seeding and Propagation

• Pathological tau behaves like prion protein
• Cell-to-cell transmission via synaptic connections
• Implications for stopping spread with therapeutics

Tau Post-Translational Modifications

• O-GlcNAc crosstalk with phosphorylation
• Acetylation as pathological modification ( Lys280)
• Truncation at Asp421 generates toxic fragments

Tau in Glial Cells

• Astrocytes can accumulate tau pathology
• Microglial involvement in spread and inflammation
• Non-neuronal tau in disease progression

Tau-Based Diagnostic Criteria

Recent research has advanced diagnostic frameworks [24]:

• ATN (Amyloid, Tau, Neurodegeneration) research framework
• Biomarker-based AD staging
• Tau-centered therapeutic trials
• Precision medicine approaches based on pathology

Future Directions

Tau research continues to evolve with several key areas:

• Understanding tau propagation mechanisms and stopping spread
• Developing better biomarkers for early detection
• Targeting tau in pre-symptomatic stages
• Combination therapies targeting amyloid and tau
• Personalized approaches based on tau biology

Conclusion

Tau pathology represents a critical target for neurodegenerative disease therapy. The strong correlation between tau burden and cognitive decline makes it an attractive therapeutic target. While challenges remain, advances in biomarkers, models, and therapeutic approaches offer hope for disease-modifying treatments for AD and related tauopathies.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References